 - Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine Candidates was Funded Through Competitive Federal Grants and has Been Published in Peer Reviewed Scientific Publications - - MVP Combines Protein Nanoparticle-Based Adjuvants Linked to Infectious Disease Peptides for Rapid Development of Thermally Stable and Easy to Administer Vaccines - NOVATO, CA ACCESSWIRE September 21, 2021 Mosaic ImmunoEngineering Inc. Mosaic or the Company, OTCQB:CPMV, a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced that it has licensed rights to develop and commercialize several novel vaccine candidates that have been validated in pre-clinical infectious disease studies including SARS-CoV-2 and other infectious disease applications. The new technology was licensed from the University of California San Diego UC San Diego and expands the Companys Modular Vaccine Platform MVP for infectious diseases. 